Board

The Board of Oslo Cancer Cluster is made up of nine highly skilled and experienced member representatives whom reflect the oncology value chain from research to pharmaceutical industry.

Henrik Lund

Henrik Lund

Chairman of the Board

E-mail: henriklu@online.no

Henrik Lund has been a board member since 2008. Lund is an MD PhD from University of Oslo and received his post-doctoral training at UC San Francisco in lipidology.

In 2005 – 2010 Lund served as VP of AstraZenecas Marketing Company clinical development group. He has also served as CEO and Chairman of the Board of several Norwegian biotech/life science companies.

Lund is now CEO of Regenics AS, a partner of Life Capitol AS and Chairman of the Board of Arctic Nutrition AS.

Ludvik Sandnes

Ludvik Sandnes

Board Member

E-mail: ludvik.sandnes@ekornhuset.no

Ludvik Sandnes has more than 40 years of experience from international corporate finance, banking and asset management.

He is Chairman of the Board of Nordic Nanovector ASA, listed on the Oslo Stock Exchange, and board member of Oncoinvent AS, Oslo Cancer Cluster, Godthaab Helse og Rehabilitering and Pioner Fonds AS.

Ludvik holds degrees as Siviløkonom and Certified European Financial Analyst (AFA) from the Norwegian School of Economics and Business Administration.

Sandnes became a member of the Oslo Cancer Cluster board in 2015.

Gunnar Sæter

Gunnar Sæter

Board Member

E-mail: Gunnar.Sater@rr-research.no

Professor Gunnar Sæter is the Head of the Institute for Cancer Research at Oslo University Hospital, where he leads the basic and translational cancer research at the Comprehensive Cancer Center. His previous position was Global Director of Scientific Affairs for Merck (MSD) Oncology. Sæter joined the Board of Oslo Cancer Cluster in May 2014, but he was previously a board member from 2010 - 2011.

Professor Sæter has broad experience in clinical oncology, cancer research and hospital administration, both at a national and international level. He has participated and chaired multiple governmental bodies and advisory committees on cancer care, cancer research and health care organization.

Unni Hjelmaas

Unni Hjelmaas

Board Member

E-mail: uh@bionorpharma.com

Unni Hjelmaas is CEO of Bionor Pharma and joined the board of Oslo Cancer Cluster in May 2014.

Hjelmaas has extensive senior management experience from Roche, and is former CEO of Lytix Biopharma. Hjelmaas has substantial experience from oncology, life cycle management, international strategy and marketing experience from Roche HQ in Basel.

Unnni Hjelmaas is also former Chairman of the Board of the Norwegian Pharma Industry Association. She has a Cand.pharm degree in Pharmacy from the University of Oslo.

Ingvild Hagen

Ingvild Hagen

Board Member

E-mail: ingvild.hagen@roche.com

Ingvild Hagen is Director of Portfolio Strategy in Roche Norway and joined the board of Oslo Cancer Cluster in May 2014.

She has been working with oncology within Norwegian affililates of international pharmaceutical companies for 17 years. The last 10 years has been spent in Roche, one of the leading oncology companies worldwide, where she holds a position in the local leadership team.

Her experience includes planning and execution of clinical trials and achieving market access for new drugs, but her main experience is a variety of positions within sales and marketing.

Hagen holds a Master of Science degree in Biophysics and Medical Technology from the Norwegian Technology University in Trondheim.

Bjørn Tore Gjertsen

Bjørn Tore Gjertsen

Board Member

E-Mail: bjorn.gjertsen@uib.no

Bjørn Tore Gjertsen jr. is Professor at Department of Clinical Science at the University of Bergen, and Clinical Chief at the early phase Clinical Trials Unit at Haukeland University Hospital – Helse Bergen. He joined the board of Oslo Cancer Cluster in May 2014.

Gjertsen is consultant hematologist with special focus on acute and chronic myeloid leukemia. He participates as project leader and principle investigator in the Centre of Excellence in Cancer Biomarkers CCBIO and the medical visualization cluster MedViz, University of Bergen and Helse Bergen, with special interest in early phase clinical trials with integrated fuctonal screens and accompanied diagnostics.

Gjertsen is also board member in two small biotech companies developing new cancer therapy.

Kirsten Haugland

Kirsten Haugland

Board Member

E-Mail: Kirsten.Haugland@kreftforeningen.no

Kirsten Haugland is Head of the Research and Prevention Department at the Norwegian Cancer Society. She joined the Board of Oslo Cancer Cluster in May 2015.

Kirsten Haugland has been working in Norwegian Cancer Society since 2010. She has 25 years’ experience from hospitals and more than 15 in leadership positions. During many years in cancer care for children and their families, Haugland focused on organizational development and patient involvement. Ms. Haugland is also responsible for and engaged in different leadership development programs. Ms. Haugland holds a Master of Health Economics and Health Management from the University of Oslo and a Bachelor in Nursing with specialization in cancer care.

Ms. Haugland has participated to several leadership programs, among others an executive management program in strategy and innovation at INSEAD in 2014.

Svein Stølen

Svein Stølen

Board Member

E-Mail: svein.stolen@mn.uio.no

Svein Stølen is a professor of inorganic chemistry, and have had extended research stays in Nagoya and Bristol. He chaired the Department of Chemistry for 4 years (2009-2012), and the Centre for Materials Science and Nanotechnology for 2 years (2010-11).

He has recently been or is a member of the board of the Institute for Energy Technology, CIENS (the collaboration platform between UiO and the institute sector within environmental science), NANO2021 (the nanotechnology programme of the National Research Council (NRC)), and also the board of the NRC Division for Science (2015-).

Also, he has recently been given the task of chairing the board of the largest UiO strategic commitment ever, the University of Oslo: Life sciences-initiative. Simultaneously, he is a board member of a second UiO strategic initiative, UiO:Energy. He joined the Board of Oslo Cancer Cluster in September 2016.

Ole Dahlberg

Ole Dahlberg

Board Member

E-Mail: ole.dahlberg@thermofisher.com

Ole Dahlberg is the CEO of ThermoFisher Scientific and joined the borad of Oslo Cancer Cluster in June 2016.

Kaare R. Norum

Kaare R. Norum

Honourable Member of the Board

E-mail: krnorum@gmail.com

Kaare R. Norum is Professor Emeritus at the University of Oslo and Honourable Member of the Oslo Cancer Cluster and the Board of the Oslo Cancer Cluster. Norum is the initiator of both the Oslo Cancer Cluster and the Oslo Cancer Cluster Innovation Park, together with Jónas Einarsson, CEO of the Radium Hospital Research Foundation.

Norum was Professor in Medicine and Nutrition from 1972 until 2002 at Institute for Nutrition Research, University of Oslo. He has chaired the National Nutrition Council of Norway for several years. He was associate Dean and then later, Dean for the Medical Faculty, University of Oslo. He also served as principal of the University of Oslo for some years.

Norum was member of the UN Commission of the Nutrition Challenges of the 21st Century and member of the Board for the WHO Multicentre Growth Reference Study. He has served as the Chair for the Reference Group of WHO project on the "Global Strategy for Diet, Physical Activity and Health” 2002-2004, and he was Chair of an Expert Group on “Counteracting Obesity in Europe” serving the European Regional Office of WHO.

He is Commander of The Royal Norwegian Order of St. Olav, and Commander of the Royal Swedish Order of the Northern Star.